GeoVax Labs Profit Margin 2006-2021 | GOVX

Current and historical gross margin, operating margin and net profit margin for GeoVax Labs (GOVX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. GeoVax Labs net profit margin as of September 30, 2021 is -1305.93%.
GeoVax Labs Annual Profit Margins
GeoVax Labs Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.002B
GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75